nodes	percent_of_prediction	percent_of_DWPC	metapath
Levetiracetam—Psychotic depression—Riluzole—amyotrophic lateral sclerosis	0.0434	0.0567	CcSEcCtD
Levetiracetam—CACNA1B—Synaptic Vesicle Pathway—UNC13A—amyotrophic lateral sclerosis	0.04	0.317	CbGpPWpGaD
Levetiracetam—Major depression—Riluzole—amyotrophic lateral sclerosis	0.0338	0.0441	CcSEcCtD
Levetiracetam—Paranoid reaction—Riluzole—amyotrophic lateral sclerosis	0.0214	0.0279	CcSEcCtD
Levetiracetam—Personality disorder—Riluzole—amyotrophic lateral sclerosis	0.021	0.0275	CcSEcCtD
Levetiracetam—White blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.0183	0.0239	CcSEcCtD
Levetiracetam—Hostility—Riluzole—amyotrophic lateral sclerosis	0.0164	0.0215	CcSEcCtD
Levetiracetam—Urine abnormality—Riluzole—amyotrophic lateral sclerosis	0.0164	0.0215	CcSEcCtD
Levetiracetam—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.016	0.0209	CcSEcCtD
Levetiracetam—SV2A—medulla oblongata—amyotrophic lateral sclerosis	0.0157	0.145	CbGeAlD
Levetiracetam—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.0155	0.0202	CcSEcCtD
Levetiracetam—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.0155	0.0202	CcSEcCtD
Levetiracetam—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.014	0.0183	CcSEcCtD
Levetiracetam—SV2A—spinal cord—amyotrophic lateral sclerosis	0.014	0.129	CbGeAlD
Levetiracetam—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.0133	0.0174	CcSEcCtD
Levetiracetam—Depersonalisation—Riluzole—amyotrophic lateral sclerosis	0.013	0.0169	CcSEcCtD
Levetiracetam—Apathy—Riluzole—amyotrophic lateral sclerosis	0.0127	0.0166	CcSEcCtD
Levetiracetam—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0165	CcSEcCtD
Levetiracetam—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.0118	0.0154	CcSEcCtD
Levetiracetam—SV2A—cerebellum—amyotrophic lateral sclerosis	0.0111	0.103	CbGeAlD
Levetiracetam—CACNA1B—medulla oblongata—amyotrophic lateral sclerosis	0.0108	0.1	CbGeAlD
Levetiracetam—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.0103	0.0134	CcSEcCtD
Levetiracetam—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00994	0.013	CcSEcCtD
Levetiracetam—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00994	0.013	CcSEcCtD
Levetiracetam—CACNA1B—spinal cord—amyotrophic lateral sclerosis	0.00967	0.0895	CbGeAlD
Levetiracetam—CACNA1B—Synaptic Vesicle Pathway—SLC1A3—amyotrophic lateral sclerosis	0.00953	0.0757	CbGpPWpGaD
Levetiracetam—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00932	0.0122	CcSEcCtD
Levetiracetam—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00927	0.0121	CcSEcCtD
Levetiracetam—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.00927	0.0121	CcSEcCtD
Levetiracetam—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00921	0.012	CcSEcCtD
Levetiracetam—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.0091	0.0119	CcSEcCtD
Levetiracetam—SV2A—brain—amyotrophic lateral sclerosis	0.00902	0.0834	CbGeAlD
Levetiracetam—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00879	0.0115	CcSEcCtD
Levetiracetam—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00823	0.0107	CcSEcCtD
Levetiracetam—CACNA1B—nervous system—amyotrophic lateral sclerosis	0.00815	0.0754	CbGeAlD
Levetiracetam—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.0079	0.0103	CcSEcCtD
Levetiracetam—CACNA1B—central nervous system—amyotrophic lateral sclerosis	0.00785	0.0726	CbGeAlD
Levetiracetam—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00782	0.0102	CcSEcCtD
Levetiracetam—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00774	0.0101	CcSEcCtD
Levetiracetam—CACNA1B—cerebellum—amyotrophic lateral sclerosis	0.00767	0.071	CbGeAlD
Levetiracetam—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00735	0.0096	CcSEcCtD
Levetiracetam—Injury—Riluzole—amyotrophic lateral sclerosis	0.00719	0.00938	CcSEcCtD
Levetiracetam—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00703	0.00918	CcSEcCtD
Levetiracetam—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00663	0.00866	CcSEcCtD
Levetiracetam—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00661	0.00862	CcSEcCtD
Levetiracetam—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.0065	0.00849	CcSEcCtD
Levetiracetam—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00645	0.00842	CcSEcCtD
Levetiracetam—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00638	0.00833	CcSEcCtD
Levetiracetam—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00626	0.00817	CcSEcCtD
Levetiracetam—CACNA1B—brain—amyotrophic lateral sclerosis	0.00623	0.0576	CbGeAlD
Levetiracetam—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00621	0.00811	CcSEcCtD
Levetiracetam—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00614	0.00802	CcSEcCtD
Levetiracetam—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.0061	0.00796	CcSEcCtD
Levetiracetam—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00583	0.00761	CcSEcCtD
Levetiracetam—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00571	0.00745	CcSEcCtD
Levetiracetam—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00571	0.00745	CcSEcCtD
Levetiracetam—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.0056	0.00731	CcSEcCtD
Levetiracetam—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00549	0.00717	CcSEcCtD
Levetiracetam—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00542	0.00708	CcSEcCtD
Levetiracetam—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00534	0.00697	CcSEcCtD
Levetiracetam—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.0052	0.00678	CcSEcCtD
Levetiracetam—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00516	0.00674	CcSEcCtD
Levetiracetam—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00509	0.00665	CcSEcCtD
Levetiracetam—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00509	0.00665	CcSEcCtD
Levetiracetam—Depression—Riluzole—amyotrophic lateral sclerosis	0.00508	0.00663	CcSEcCtD
Levetiracetam—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00496	0.00648	CcSEcCtD
Levetiracetam—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00495	0.00646	CcSEcCtD
Levetiracetam—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00481	0.00628	CcSEcCtD
Levetiracetam—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.0048	0.00627	CcSEcCtD
Levetiracetam—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00478	0.00623	CcSEcCtD
Levetiracetam—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00475	0.0062	CcSEcCtD
Levetiracetam—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00458	0.00598	CcSEcCtD
Levetiracetam—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00457	0.00597	CcSEcCtD
Levetiracetam—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00455	0.00594	CcSEcCtD
Levetiracetam—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00454	0.00592	CcSEcCtD
Levetiracetam—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00449	0.00586	CcSEcCtD
Levetiracetam—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00448	0.0355	CbGpPWpGaD
Levetiracetam—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00432	0.00564	CcSEcCtD
Levetiracetam—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00427	0.00558	CcSEcCtD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00421	0.0335	CbGpPWpGaD
Levetiracetam—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00413	0.00539	CcSEcCtD
Levetiracetam—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00412	0.00538	CcSEcCtD
Levetiracetam—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00404	0.00527	CcSEcCtD
Levetiracetam—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.004	0.00523	CcSEcCtD
Levetiracetam—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00398	0.00519	CcSEcCtD
Levetiracetam—Tension—Riluzole—amyotrophic lateral sclerosis	0.0039	0.0051	CcSEcCtD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00389	0.0309	CbGpPWpGaD
Levetiracetam—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00504	CcSEcCtD
Levetiracetam—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00385	0.00502	CcSEcCtD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00376	0.0298	CbGpPWpGaD
Levetiracetam—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00373	0.00487	CcSEcCtD
Levetiracetam—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00366	0.00477	CcSEcCtD
Levetiracetam—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00357	0.00467	CcSEcCtD
Levetiracetam—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00356	0.00465	CcSEcCtD
Levetiracetam—Cough—Riluzole—amyotrophic lateral sclerosis	0.00347	0.00453	CcSEcCtD
Levetiracetam—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00345	0.0045	CcSEcCtD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00344	0.0273	CbGpPWpGaD
Levetiracetam—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00339	0.00442	CcSEcCtD
Levetiracetam—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00339	0.00442	CcSEcCtD
Levetiracetam—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00339	0.00442	CcSEcCtD
Levetiracetam—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00337	0.00441	CcSEcCtD
Levetiracetam—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00336	0.00439	CcSEcCtD
Levetiracetam—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00327	0.00427	CcSEcCtD
Levetiracetam—CACNA1B—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00323	0.0256	CbGpPWpGaD
Levetiracetam—Infection—Riluzole—amyotrophic lateral sclerosis	0.00323	0.00421	CcSEcCtD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00319	0.0254	CbGpPWpGaD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00319	0.0254	CbGpPWpGaD
Levetiracetam—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00318	0.00416	CcSEcCtD
Levetiracetam—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00318	0.00415	CcSEcCtD
Levetiracetam—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00315	0.00412	CcSEcCtD
Levetiracetam—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00309	0.00404	CcSEcCtD
Levetiracetam—CACNA1B—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00298	0.0237	CbGpPWpGaD
Levetiracetam—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00296	0.00386	CcSEcCtD
Levetiracetam—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00294	0.00383	CcSEcCtD
Levetiracetam—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00292	0.00381	CcSEcCtD
Levetiracetam—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00289	0.00377	CcSEcCtD
Levetiracetam—CACNA1B—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00288	0.0229	CbGpPWpGaD
Levetiracetam—SV2A—Disease—TPK1—amyotrophic lateral sclerosis	0.00287	0.0228	CbGpPWpGaD
Levetiracetam—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00286	0.00373	CcSEcCtD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.00285	0.0226	CbGpPWpGaD
Levetiracetam—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00282	0.00368	CcSEcCtD
Levetiracetam—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00366	CcSEcCtD
Levetiracetam—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00365	CcSEcCtD
Levetiracetam—Pain—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00362	CcSEcCtD
Levetiracetam—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00362	CcSEcCtD
Levetiracetam—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00268	0.00349	CcSEcCtD
Levetiracetam—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00265	0.00347	CcSEcCtD
Levetiracetam—CACNA1B—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00263	0.0209	CbGpPWpGaD
Levetiracetam—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00257	0.00335	CcSEcCtD
Levetiracetam—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00257	0.00335	CcSEcCtD
Levetiracetam—CACNA1B—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.00245	0.0194	CbGpPWpGaD
Levetiracetam—CACNA1B—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.00245	0.0194	CbGpPWpGaD
Levetiracetam—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00312	CcSEcCtD
Levetiracetam—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00233	0.00304	CcSEcCtD
Levetiracetam—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.0023	0.003	CcSEcCtD
Levetiracetam—SV2A—Disease—VTA1—amyotrophic lateral sclerosis	0.00229	0.0182	CbGpPWpGaD
Levetiracetam—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00222	0.0029	CcSEcCtD
Levetiracetam—CACNA1B—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00218	0.0173	CbGpPWpGaD
Levetiracetam—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00215	0.0028	CcSEcCtD
Levetiracetam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.0021	0.0167	CbGpPWpGaD
Levetiracetam—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00269	CcSEcCtD
Levetiracetam—Rash—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00267	CcSEcCtD
Levetiracetam—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00267	CcSEcCtD
Levetiracetam—Headache—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00266	CcSEcCtD
Levetiracetam—ABCB1—embryo—amyotrophic lateral sclerosis	0.00198	0.0183	CbGeAlD
Levetiracetam—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00252	CcSEcCtD
Levetiracetam—SV2A—Disease—CHMP2B—amyotrophic lateral sclerosis	0.00174	0.0138	CbGpPWpGaD
Levetiracetam—SV2A—Disease—PLB1—amyotrophic lateral sclerosis	0.00157	0.0125	CbGpPWpGaD
Levetiracetam—SV2A—Disease—VCP—amyotrophic lateral sclerosis	0.0014	0.0111	CbGpPWpGaD
Levetiracetam—ABCC2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00134	0.0107	CbGpPWpGaD
Levetiracetam—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.00126	0.0117	CbGeAlD
Levetiracetam—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.00113	0.0104	CbGeAlD
Levetiracetam—SV2A—Disease—CST3—amyotrophic lateral sclerosis	0.00101	0.00798	CbGpPWpGaD
Levetiracetam—ABCC2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000983	0.0078	CbGpPWpGaD
Levetiracetam—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000949	0.00878	CbGeAlD
Levetiracetam—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000914	0.00846	CbGeAlD
Levetiracetam—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000893	0.00827	CbGeAlD
Levetiracetam—ABCC2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000758	0.00602	CbGpPWpGaD
Levetiracetam—SV2A—Disease—CASP9—amyotrophic lateral sclerosis	0.000731	0.0058	CbGpPWpGaD
Levetiracetam—ABCB1—brain—amyotrophic lateral sclerosis	0.000726	0.00671	CbGeAlD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000649	0.00515	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000644	0.00512	CbGpPWpGaD
Levetiracetam—SV2A—Disease—ERBB4—amyotrophic lateral sclerosis	0.000626	0.00497	CbGpPWpGaD
Levetiracetam—ABCC2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000593	0.00471	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000529	0.0042	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.00052	0.00413	CbGpPWpGaD
Levetiracetam—SV2A—Disease—APOE—amyotrophic lateral sclerosis	0.000484	0.00384	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.000419	0.00332	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000415	0.0033	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.00037	0.00294	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000364	0.00289	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000353	0.0028	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000353	0.0028	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000353	0.0028	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000332	0.00264	CbGpPWpGaD
Levetiracetam—SV2A—Disease—PTGS2—amyotrophic lateral sclerosis	0.000332	0.00263	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000315	0.0025	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000303	0.00241	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000257	0.00204	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.000219	0.00174	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000216	0.00172	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.000215	0.0017	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000207	0.00164	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000195	0.00155	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000187	0.00149	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000187	0.00149	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000186	0.00148	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000171	0.00136	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000166	0.00132	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000166	0.00132	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000159	0.00126	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00015	0.00119	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000148	0.00117	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.00014	0.00111	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000135	0.00108	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000116	0.000924	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000108	0.000858	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000103	0.000815	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	9.47e-05	0.000752	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	9.17e-05	0.000728	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	7.78e-05	0.000617	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	6.93e-05	0.00055	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.18e-05	0.000332	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.84e-05	0.000305	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	3.16e-05	0.000251	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.17e-05	0.000172	CbGpPWpGaD
